UT Soutwestern | Strategic Alliance Partners

October 06, 2021

Larry Anderson, MD, PhD, discusses the methods utilized in the phase 2 KarMMa trial in multiple myeloma.

September 16, 2021

Larry Anderson, MD, PhD, discusses the challenges faced with CAR T-cell therapy in patients with multiple myeloma.

September 04, 2021

Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.

September 04, 2021

Nicole Rich, MD, discusses the prevalence of cachexia in hepatocellular carcinoma.

August 20, 2021

Hans Hammers, MD, PhD,discusses the safety profile of lenvatinib in combination with pembrolizumab in renal cell carcinoma.

August 12, 2021

Neoadjuvant stereotactic radiation followed by radical nephrectomy and thrombectomy is a safe and feasible treatment option for patients with renal cell carcinoma and inferior vena cava tumor thrombus.

June 02, 2021

Hans Hammers, MD, PhD, discusses the potential utility of HIF-2α inhibitors in renal cell carcinoma.

May 12, 2021

Hans Hammers, MD, PhD, discusses the importance of assessing quality of life in renal cell carcinoma.

May 03, 2021

Amy Jones, MD, discusses future research efforts in pancreatic cancer.

May 03, 2021

Syed Kazmi, MD, an oncologist at The University of Texas Southwestern Medical Center, discusses key treatment considerations for young patients with onset colorectal cancer.

April 13, 2021

Syed Kazmi, MD, highlights the go-to regimens for patients with mCRC.

March 19, 2021

Syed Kazmi, MD, discusses the importance of tailoring treatment to different subtypes of colorectal cancer.

March 05, 2021

Amy Jones, MD, discusses factors that can inform frontline treatment selection in pancreatic cancer.

March 02, 2021

Amit G. Singal, MD, MS, discusses the utility of frontline lenvatinib and sorafenib in hepatocellular carcinoma.

January 18, 2021

In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.

November 17, 2020

Farrukh Awan, MD, discusses the importance of risk stratification in chronic lymphocytic leukemia.

November 04, 2020

Farrukh Awan, MD, discusses the importance of collaborative care in chronic lymphocytic leukemia.

October 28, 2020

Hans Hammers, MD, PhD, discusses investigational strategies that are being used to inflame tumors in renal cell carcinoma.

October 23, 2020

Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.

October 02, 2020

David Gerber, MD, discusses the rationale to combine immunotherapy with radiation therapy in lung cancer.